Clinical Study of Jianfei Kangfu Cao in the Treatment of pSS-ILD

Study Purpose

This study will evaluate the safety and efficacy of Jianfei Kangfu Cao in the treatment of primary Sjogren's syndrome associated interstitial lung disease.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years - 75 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

1. According to the 2012 ACR classification of primary Sjogren's syndrome . 2. CT confirmed interstitial lung disease; 3. DLCO≧40%; 4. Stable treatment for at least 12 weeks; 5. Patients with good compliance should sign informed consent before the tria.

Exclusion Criteria:

1. The patient is using or has used anti pulmonary fibrosis drugs; 2. Pulmonary infection, tumor and other connective tissue diseases; 3. Chronic obstructive pulmonary disease, bronchial asthma and tuberculosis; 4. Patients with severe hypertension, diabetes and heart, liver and renal failure; 5. Women with reproductive needs; 6. Idiopathic pulmonary interstitial disease; 7. The researcher thinks that it is not suitable to participate in this experiment; 8. Participants in other clinical trials.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT04544722
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

N/A
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Shanghai University of Traditional Chinese Medicine
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Zhujing Zhu, Ph.DJianchun Mao, MasterHuanru Qu, Ph.D
Principal Investigator Affiliation Longhua HospitalLonghua HospitalLonghua Hospital
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Not yet recruiting
Countries
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Primary Sjogren's Syndrome, Interstitial Lung Disease
Additional Details

This study will be a randomized, double-blind, positive control clinical trial with a course of 24 weeks. 1. Random scheme:the DAS for Interactive Web Response System(IWRS) will be used to calculate and distribute random numbers and dispensing drugs. 2. Blind method :The test process will be in a double-blind state. 3. Control drug: The lung rehabilitation training will be used as control in this trial.

Arms & Interventions

Arms

Experimental: Jianfei Kangfu Cao

The original treatment and Jianfei Kangfu Cao, once a day, 30 minutes each time.

Active Comparator: Lung rehabilitation training

The original treatment and the lung rehabilitation training, once a day, 30 minutes each time.

Interventions

Behavioral: - Jianfei Kangfu Cao

The original treatment and Jianfei Kangfu Cao, once a day, 30 minutes each time.

Behavioral: - lung rehabilitation training

The original treatment and the lung rehabilitation training, once a day, 30 minutes each time.

Contact Information

This trial has no sites locations listed at this time. If you are interested in learning more, you can contact the trial's primary contact:

Zhujing Zhu, Ph.D

zzj01@hotmail.com

+8613816914874

For additional contact information, you can also visit the trial on clinicaltrials.gov.

Terms of Service

The PFF does not promote or represent that any investigational new drugs mentioned are safe or effective. The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. For a full description of terms please refer to our Terms, Conditions & Privacy.

Back to Top
footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >